Stay updated on Hemostatic Activity Post LAAO Clinical Trial
Sign up to get notified when there's something new on the Hemostatic Activity Post LAAO Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2F8zL6hqTsS4iaeFkPcX8PbzuYCYw.uncropped.jpg&w=3840&q=75)
Latest updates to the Hemostatic Activity Post LAAO Clinical Trial page
- ChecktodayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has been updated to version v2.10.0, replacing the previous version v2.9.7.SummaryDifference0.7%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more Show more Revision: v2.9.0' has recently changed to 'Show less FDA Drug and Device Resources Show less Design Details Observational Model : Cohort Time Perspective: Prospective Groups and Interventions Intervention/Treatment Device : Left Atrial Appendage Occlusion Interventional left atrial appendage occlusion with the Amulet or Watchman device Other Names: Left Atrial Appendage Closure Primary Outcome Measures Outcome Measure Measure Description Time Frame Change in coagulation activity Coagulation activity as measured by prothrombin fragment 1+2 7 days, 14 days, 90 days Secondary Outcome Measures Outcome Measure Measure Description Time Frame Change in platelet activity Incl. platelet count, turnover, and aggregation 7 days, 14 days, 90 days Additional measures of changes in coagulation and contact activation Incl. thrombin generation, fibrinogen, d-dimer and coagulation factors 7 days, 14 days, 90 days Change in endothelial activation and response Incl. changes in soluble thrombomodulin, syndecan-1, selectin and von Willebrand factor 7 days, 14 days, 90 days Non-procedural bleeding events As defined by the Bleeding Academic Research Consortium 7 days, 14 days, 90 days Radiographical evidence of device endothelization On CT indicated by no contrast patency distal to the LAAO device. 7 days, 14 days, 90 days Radiographically confirmed device-related thrombosis Defined as high grade HAT on follow-up cardiac CT or TEE 7 days, 14 days, 90 days Additional Relevant MeSH Terms Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes Atrial Fibrillation Studies a U.S. FDA-Regulated Drug Product No Studies a U.S. FDA-Regulated Device Product No Revision: v2.9.1'SummaryDifference21%
Stay in the know with updates to Hemostatic Activity Post LAAO Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Hemostatic Activity Post LAAO Clinical Trial page.